Danaher Corporation (DHR) News
Track canonical SquawkNews coverage tagged to DHR, Danaher Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 36 indexed stories across 14 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Danaher Appoints Julie Sawyer Montgomery CEO
Danaher names new CEO
EQUITY | Aug 03, 2026, 08:16 PM UTC
L
Largest discount to VWAP OSK (-2.89%) AMKR (-2.48%) NRG (-2.34%) MTDR (-2.31%) DHR (-2.22%) W (-2.07%) BKR (-1.94%) FANG (-1.79%) WELL (-1.6
Largest discount to VWAP OSK (-2.89%) AMKR (-2.48%) NRG (-2.34%) MTDR (-2.31%) DHR (-2.22%) W (-2.07%) BKR (-1.94%) FANG (-1.79%) WELL (-1.68%) EME (-1.66%) (Russell 1000 names)
EQUITY | Jul 28, 2026, 03:22 PM UTC
L
Outperformers vs S&P sector ETFs (% chg vs ETF) Consumer Discretionary (XLY) - WYNN +7.20%, TSCO +6.63%, LVS +5.93%, YUM +4.79%, GRMN +4.78%
Outperformers vs S&P sector ETFs (% chg vs ETF) Consumer Discretionary (XLY) - WYNN +7.20%, TSCO +6.63%, LVS +5.93%, YUM +4.79%, GRMN +4.78% Consumer Staples (XLP) - CASY +3.38%, MO +1.29%, ADM +1.01%, PEP +0.83%, BG +0.
RATES | Jul 23, 2026, 04:00 PM UTC
L
Largest premium to VWAP RLI (+4.71%) ROL (+3%) WEX (+2.99%) ORI (+2.48%) LLY (+2.09%) ALLE (+2.08%) ALK (+2.04%) IBM (+2.03%) DHR (+1.78%) L
Largest premium to VWAP RLI (+4.71%) ROL (+3%) WEX (+2.99%) ORI (+2.48%) LLY (+2.09%) ALLE (+2.08%) ALK (+2.04%) IBM (+2.03%) DHR (+1.78%) LVS (+1.78%) (Russell 1000 names)
EQUITY | Jul 23, 2026, 03:42 PM UTC
L
DHR +5.6% at highs, bouncing off of Tuesday's sell off post lower guide, being helped by better results in Life Science/tools today TMO and
DHR +5.6% at highs, bouncing off of Tuesday's sell off post lower guide, being helped by better results in Life Science/tools today TMO and SOAGY Sartorius in Europe
EQUITY | Jul 23, 2026, 03:30 PM UTC
L
DHR Danaher saw its price target lowered to $220 from $260 at Stifel. Headline numbers for the second quarter were strong, but analysts said
DHR Danaher saw its price target lowered to $220 from $260 at Stifel. Headline numbers for the second quarter were strong, but analysts said the underperformance in its key bioprocessing business was "the obvious focal p
EQUITY | Jul 22, 2026, 01:09 PM UTC
L
DHR PT reduced from $235 to $200, maintains Buy @ GUGG
DHR PT reduced from $235 to $200, maintains Buy @ GUGG
EQUITY | Jul 22, 2026, 12:46 PM UTC
L
DHR Reiterate Buy and lower PT from $260 to $220 after results @ Stifel
DHR Reiterate Buy and lower PT from $260 to $220 after results @ Stifel
EQUITY | Jul 22, 2026, 11:12 AM UTC
H
Crude Oil Surges 2%; 3M Shares Gain After Q2 Results
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 350 points on Tuesday. The Dow traded up 0.70% to 52,204.49 while the NASDAQ climbed 1.30% to 25,838.45. The S&P 500 also rose, gain
RATES | Jul 21, 2026, 06:18 PM UTC
H
Why Danaher Stock Just Tanked 14%
Danaher Corp. (NYSE: DHR ) stock fell sharply Tuesday after the life sciences company lowered its 2026 core revenue growth forecast and trimmed its outlook for its Bioprocessing business, despite reporting second-quarter
EARNINGS | Jul 21, 2026, 02:12 PM UTC
H
Transcript: Danaher Q2 2026 Earnings Conference Call
Danaher (NYSE: DHR ) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. APIs provide real-time access to earnings call transcripts and financial data. Vi
EARNINGS | Jul 21, 2026, 01:36 PM UTC
H
Morning Movers: Equifax sinks following second quarter earnings
Stock futures are pointing higher as investors attempt to build on Monday's rebound, with technology shares leading premarket gains ahead of a stretch of earnings from some of the market's largest companies. The focus th
RATES | Jul 21, 2026, 01:03 PM UTC
L
DHR Danaher exec notes a more constructive government policy environment would be needed to support a recovery in research funding - conf ca
DHR Danaher exec notes a more constructive government policy environment would be needed to support a recovery in research funding - conf call
RATES | Jul 21, 2026, 12:41 PM UTC
H
among early movers from the earnings calendar this morning gainers MMM +6.3%, VMI +4.6%, MBWM +1.5%, GPC +1.1%, HAS +1.0%, VICR +0.9%, OFG +
among early movers from the earnings calendar this morning gainers MMM +6.3%, VMI +4.6%, MBWM +1.5%, GPC +1.1%, HAS +1.0%, VICR +0.9%, OFG +0.8%, MRSH +0.5% decliners DHR -13.0%, MSCI -11.6%, EFX -9.4%, NOC -4.0%, HAL -3
EARNINGS | Jul 21, 2026, 12:37 PM UTC
H
DHR -12% premarket after results, guidance; Peers A -3%, TMO -3%, RVTY, ILMN down about 2%
DHR -12% premarket after results, guidance; Peers A -3%, TMO -3%, RVTY, ILMN down about 2%
EARNINGS | Jul 21, 2026, 12:30 PM UTC
H
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Tuesday. Shares of Danaher Corp (NYSE: DHR ) fell sharply in pre-market trading following second-quarter results. Danaher p
EARNINGS | Jul 21, 2026, 12:01 PM UTC
H
Earnings Calendar: • Earnings Before the Open: ALLY AUB CCBG DHI DHR EFX FOR GM GPC HAL HAS KEY MBWM MMM MRSH MSCI Noc NVS PEBO SCHW SYF UCB
Earnings Calendar: • Earnings Before the Open: ALLY AUB CCBG DHI DHR EFX FOR GM GPC HAL HAS KEY MBWM MMM MRSH MSCI Noc NVS PEBO SCHW SYF UCB VICR VMI • Earnings After the Close: AIR ALK BWB CB COF EQT EWBC FFBC HAFC HWC
EARNINGS | Jul 21, 2026, 10:52 AM UTC
L
DHR falls -10% after cutting FY outlook FY adj rev growth to 3-4% (down from prior view of up 3%-6%)
DHR falls -10% after cutting FY outlook FY adj rev growth to 3-4% (down from prior view of up 3%-6%)
EQUITY | Jul 21, 2026, 10:47 AM UTC
L
DHR Danaher shares down 9% premarket after Q2 results
DHR Danaher shares down 9% premarket after Q2 results
EQUITY | Jul 21, 2026, 10:21 AM UTC
H
DHR Danaher RESULTS: Q2, Q2 Operating Cash Flow $1.500B, Q2 ADJ EPS $1.94 vs. EST $1.83, Q2 EPS $1.23, Q2 REV $6.265B vs. EST $6.102B, Q2 RE
DHR Danaher RESULTS: Q2, Q2 Operating Cash Flow $1.500B, Q2 ADJ EPS $1.94 vs. EST $1.83, Q2 EPS $1.23, Q2 REV $6.265B vs. EST $6.102B, Q2 REV $6.265B vs. EST $6.102B, Danaher Earnings Notes:, Outlook FY ADJ EPS $8.45-8.6
RATES | Jul 21, 2026, 10:21 AM UTC
L
Danaher raises FY26 adjusted EPS view to $8.45-$8.60 from $8.35-$8.55
Consensus is $8.50.
EQUITY | Jul 21, 2026, 10:03 AM UTC
L
Danaher sees Q3 non-GAAP core revenue up 2%-3% y/y
Danaher sees Q3 non-GAAP core revenue up 2%-3% y/y
EARNINGS | Jul 21, 2026, 10:02 AM UTC
L
Danaher reports Q2 adjusted EPS $1.94, consensus $1.84
Reports Q2 revenue...
EQUITY | Jul 21, 2026, 10:02 AM UTC
H
Danaher Raises FY2026 Adj EPS Guidance from $8.35-$8.55 to $8.45-$8.60 vs $8.45 Est
Danaher (NYSE: DHR ) raises FY2026 Adj EPS guidance from $8.35-$8.55 to $8.45-$8.60 vs $8.45 analyst estimate..
EARNINGS | Jul 21, 2026, 10:01 AM UTC
H
Danaher Could Swing $7.33 Billion in Value After Earnings
Earnings are back in focus on July 21, 2026, and the options market is already laying down markers for how violent the post-print reaction could be. For retail investors, implied moves can help frame risk around the repo
RATES | Jul 20, 2026, 07:29 PM UTC
L
Implied EPS movers for tomorrow AM: DHR +/-5.0%, NOC +/-7.2%, MRSH +/-5.9%, MMM +/-5.2%, GM +/-5.5%, DHI +/-5.3%, HAL +/-3.9%, MSCI +/-7.2%,
Implied EPS movers for tomorrow AM: DHR +/-5.0%, NOC +/-7.2%, MRSH +/-5.9%, MMM +/-5.2%, GM +/-5.5%, DHI +/-5.3%, HAL +/-3.9%, MSCI +/-7.2%, GPC +/-8.5%, SYF +/-7.5%, KEY +/-5.7%, EFX +/-10.7%, VICR +/-26.3%, HAS +/-9.4%
EARNINGS | Jul 20, 2026, 05:59 PM UTC
H
Earnings were busy this week...but gets busier next week as highlights include: --Mon: STLD ZION --Tues: DHR SCHW COF CB HAL MMM --Wed: GEV
Earnings were busy this week...but gets busier next week as highlights include: --Mon: STLD ZION --Tues: DHR SCHW COF CB HAL MMM --Wed: GEV T PM GOOGL TXN TSLA IBM NOW --Thurs: TMO LMT RTX BX TMUS UNP INTC AAL CMCSA DOW
EARNINGS | Jul 17, 2026, 05:19 PM UTC
L
Near 200dma resistance HON DHR FNF MLI MCK BRKB SEB BJ VLTO RPM EMR PCTY TOST
Near 200dma resistance HON DHR FNF MLI MCK BRKB SEB BJ VLTO RPM EMR PCTY TOST
EQUITY | Jul 16, 2026, 03:26 PM UTC
L
TMO DHR WAT A in Tools and GH CAI in Diagnostics remain Buy rated in Q2 preview @ GSCO
TMO DHR WAT A in Tools and GH CAI in Diagnostics remain Buy rated in Q2 preview @ GSCO
EQUITY | Jul 15, 2026, 12:17 PM UTC
H
TMO DHR RGEN SOAGY Bioprocessing Names Likely to Deliver Most 'Leverage' in Tools This Earnings Season @ KEYB
TMO DHR RGEN SOAGY Bioprocessing Names Likely to Deliver Most 'Leverage' in Tools This Earnings Season @ KEYB
EARNINGS | Jul 15, 2026, 11:14 AM UTC
L
DHR - Linden Capital Partners And Audax Private Equity To Sell StatLab Medical Products To Leica Biosystems, An Operating Company Of Danaher
DHR - Linden Capital Partners And Audax Private Equity To Sell StatLab Medical Products To Leica Biosystems, An Operating Company Of Danaher; Financial Terms Not Disclosed
EQUITY | Jul 14, 2026, 09:34 PM UTC
H
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover
Qiagen NV (NYSE: QGEN ) is drawing renewed investor attention after reports that several private equity firms are evaluating a potential takeover of the molecular diagnostics company. The stock surged 10.5% in the previo
MACRO | Jul 10, 2026, 01:26 PM UTC
L
Evercore ISI Adjusts Price Target on Danaher to $230 From $232
() -- Danaher (DHR) has an average rating of buy and mean price target of $241.95, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks and research firms in North Am
EQUITY | Jul 06, 2026, 01:21 PM UTC
L
Did Danaher Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Did Danaher Corporation Insiders Breach their Fiduciary
EQUITY | Jul 03, 2026, 04:26 PM UTC
M
Masimo Gets FDA Clearance
Masimo receives FDA clearance for opioid-induced respiratory depression detection capability combined into its Radius VSM
EQUITY | Jun 22, 2026, 12:10 PM UTC
M
DHR Receives FDA Clearance
DHR Masimo receives FDA 510(k) clearance for AI-enabled opioid-induced respiratory depression detection on Radius VSM
EQUITY | Jun 22, 2026, 12:00 PM UTC